Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy

Conditions:   Hematopoietic and Lymphoid Cell Neoplasm;   Malignant Solid Neoplasm;   Symptomatic COVID-19 Infection Laboratory-Confirmed Interventions:   Other: Best Practice;   Drug: Leflunomide;   Drug: Placebo Administration Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials